KRAS and neoplasm: Similarly, bioluminescent cytotoxicity assays following co-culture of CAR-redirected T cells with KRAS peptide–loaded FLuc+ T2 cells as well as FLuc expressing NCI-H441 and CFPAC-1 tumor cells at different E:T ratios for 12 h revealed that KRASG12V-STII CAR T cells elicited up to 70% cytotoxicity to KRASG12V peptide–loaded T2 targets at an E:T ratio of 20:1, while KRASG12V-IgFc CAR T cells reached 60% cytolytic activity at the same E:T ratio (Fig. 4B).